Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

• المؤلفون الرئيسيون: Calvin J. Cohen, Jean Michel Molina, Pedro Cahn, Bonaventura Clotet, Jan Fourie, Beatriz Grinsztejn, Hao Wu, Margaret A. Johnson, Michael Saag, Khuanchai Supparatpinyo, Herta Crauwels, Eric Lefebvre, Laurence T. Rimsky, Simon Vanveggel, Peter Williams, Katia Boven
• التنسيق: دورية
• منشور في: 2018
• الموضوعات: Medicine
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84862777419&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/51904
• المؤسسة: Chiang Mai University

Background: Pooled analysis of phase 3, double-blind, doubledummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz. Methods: Treatment-naive HIV-1-infected adults were randomized 1:1 to rilpivirine 25 mg once daily or efavirenz 600 mg once daily, with background tenofovir disoprox...